Amneal's CREXONT Shows 3+ Hour Daily 'Good On' Time Boost in Parkinson's Study
Event summary
- Amneal's Phase 4 ELEVATE-PD study (n=111) showed CREXONT increased 'Good On' time by 3.07 hours for patients switching from RYTARY
- Patients switching from immediate-release carbidopa/levodopa saw a 3.40-hour increase in 'Good On' time
- CREXONT reduced daily 'Off' time by up to 3.18 hours across treatment groups
- Study presented at the 2026 American Academy of Neurology annual meeting
- Most common adverse events included dizziness (9.0%), nausea (7.2%), and falls (7.2%)
The big picture
Amneal's positive Phase 4 results for CREXONT come as Parkinson's disease treatment options expand, with patients increasingly seeking therapies that offer longer symptom control and fewer dosing interruptions. The study's findings position CREXONT as a potential market disruptor in the $5 billion global Parkinson's disease drug market, where extended-release formulations are gaining traction. The results may also influence payer decisions as they evaluate the cost-effectiveness of newer therapies compared to established treatments.
What we're watching
- Competitive Positioning
- Whether CREXONT's demonstrated efficacy can capture market share from established Parkinson's treatments like RYTARY
- Regulatory Pathway
- The pace at which Amneal can expand CREXONT's approved indications based on these Phase 4 results
- Commercialization Strategy
- How Amneal will leverage these results to differentiate CREXONT in the competitive Parkinson's disease market
Related topics